Amarin Corporation plc

Equities

AMRN

US0231112063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.8749 ^USD	+1.72%		+1.82%	+0.56%

Apr. 19	European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	MT
Apr. 18	European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	MT

Amarin Corporation plc Reports Earnings Results for the Full Year Ended December 31, 2023

February 29, 2024 at 07:06 am EST

Amarin Corporation plc reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 306.91 million compared to USD 369.19 million a year ago. Net loss was USD 59.11 million compared to USD 105.8 million a year ago.

Basic loss per share from continuing operations was USD 0.15 compared to USD 0.26 a year ago. Diluted loss per share from continuing operations was USD 0.15 compared to USD 0.26 a year ago.

Latest news about Amarin Corporation plc

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 10	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
Amarin Corporation plc Announces New Reduce-It® Analyses Show Vascepa®/Vazkepa® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	Apr. 06	CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	Apr. 05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Apr. 03	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	Mar. 26	MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday	Mar. 20	MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading	Mar. 18	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12	MT
European Equities Traded in the US as American Depositary Receipts Decline Tuesday	Mar. 05	MT
European Equities Traded in the US as American Depositary Receipts Rise Monday Afternoon	Mar. 04	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat	Mar. 01	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Feb. 29	MT
Transcript : Amarin Corporation plc, Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Amarin Corporation plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Amarin Corporation plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Earnings Flash (AMRN) AMARIN CORPORATION Posts Q4 Revenue $74.7M, vs. Street Est of $71.1M	Feb. 29	MT
Earnings Flash (AMRN) AMARIN CORPORATION Posts Q4 EPS $-0.01, vs. Street Est of $-0.03	Feb. 29	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Feb. 28	MT

Chart Amarin Corporation plc

Duration

Period

More charts

Company Profile

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Amarin Corporation plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.8749 USD

Average target price

1.083 USD

Spread / Average Target

+23.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AMARIN CORPORATION PLC	+0.56%	359M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs